Evidence map›Paper›PMID 18712323›Full record

ArticleDer Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete2009

[Possibilities and limits for treating psoriasis with biologics. Case reports].

A Süss, A Colsman, J C Simon, M Sticherling

Abstract readCase ReportsEnglish Abstract
PubMed Publisher
In one paragraph

Article in Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

A SüssKlinik und Poliklinik für Dermatologie, Allergologie und Venerologie, Universitätsklinikum Leipzig, Leipzig.
A Colsman
J C Simon
M Sticherling

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The availability of biologics for the therapy of psoriasis has radically changed the options for systemic therapy of this disease. Their use is often coupled with a variety of restrictions--as a rule they are to be used as a 'last-line' therapy. The status of previous systemic therapy as a basic requirement for the use of biologics is analyzed and simultaneously, the possibilities of the physician to use the indication spectrum of biologics for the benefit of the patient are demonstrated by case reports.

Indexed as

AdultAgedAntibodies, MonoclonalAnti-Inflammatory AgentsBiological ProductsDermatologic AgentsFeasibility StudiesFemaleHumansMaleMiddle AgedPsoriasisTreatment OutcomeAntibodies, MonoclonalAnti-Inflammatory AgentsBiological ProductsDermatologic Agents

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.